About US
Contact us
-
New Cholesterol Treatment Guidelines ‘Hard to Swallow’ for Non-Statin Manufacturers in Cardiovascular Drug MarketUpdated guidelines for the treatment of hypercholesterolemia and atherosclerotic cardiovascular disease (ASCVD) could well give the statin market a substantial boost over the coming years, but they wi2013/11/29
-
Thermo Fisher Scientific Receives Clearance from the European Commission for its Acquisition of Life TechnologiesThermo Fisher Scientific, the world leader in serving science, today announced that it has received approval from the European Commission for its pending acquisition of Life Technologies Corporation.2013/11/28
-
FDA Approves Merck’s NOXAFIL (posaconazole) Delayed-Release TabletsMerck, known as MSD outside the US and Canada,has announced that FDA has approved NOXAFIL(posaconazole) 100 mg delayed-release tablets. NOXAFIL delayed-release tablets are a new formulation with a loa2013/11/28
-
Agalimmune Ltd Founded to Develop Immunotherapeutics for CancerAgalimmune Ltd, a biopharmaceutical company, has been created to develop innovative immunotherapeutics for the treatment of cancer, with a focus on solid tumours. The new company has been founded by a2013/11/27
-
Janssen obtains FDA approval for Olysio combination therapy for hepatitis C treatmentJanssen Therapeutics has received approval from the US Food and Drug Administration (FDA) for an NS3/4A protease inhibitor, Olysio (simeprevir), to treat chronic hepatitis C infection as part of an an2013/11/27
-
ViiV Healthcare obtains European positive opinion for HIV drug TivicayEuropean Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the marketing authorisation of ViiV Healthcare's Tivicay (dolutegravir) in com2013/11/26
-
Ophthalmology Therapeutics Market: India and China to Lead Modest GrowthThe ophthalmology therapeutics market for Dry Eye Syndrome (DES) and glaucoma in four Asia-Pacific (APAC) countries — India, Australia, China and Japan — will increase from $2.4 billion in 2012 to $3.2013/11/26
-
Genzyme gets Health Canada approval for multiple sclerosis drug AubagioSanofi firm Genzyme has received approval from Health Canada for its once-daily drug Aubagio (teriflunomide) 14mg as monotherapy to treat patients with relapsing remitting multiple sclerosis (RRMS).2013/11/25
-
CPhI Worldwide 2013 Hosted more than 34,000 Global Pharma Professionals with Expanded Content and First Annual ReportCPhI Worldwide, organised by UBM Live, celebrates the closing of its most successful show to date with pre-audit figures estimating more than 34,000 attendees and 2200 exhibitors. Held in Frankfurt, t2013/11/25
-
Q Therapeutics gets FDA orphan drug status for Q-Cells to treat ALS patientsUS-based biotechnology firm Q Therapeutics has received orphan drug designation from the US Food & Drug Administration (FDA) for its Q-Cells product (human glial restricted progenitor cells and th2013/11/22